Regenerative Biologics Supplier for Orthopedic Practices in Provo, UT

How orthopedic practices typically vet a biologics vendor

Before adding a new biologics line, most orthopedic groups and surgery centers run a short internal qualification process. That typically starts with a documentation request: certificate of analysis for the specific lot, a donor eligibility summary, and the lot release record showing sterility testing results.

Practices also commonly ask how a distributor describes its regulatory posture. We provide straightforward answers about how our supplier's donor screening, processing window, and third-party sterility testing are structured, and we point practices to the primary regulatory text in 21 CFR 1271.10 so their own compliance staff can review it directly.

NPI-verified accounts

Every Precision Biologics account is tied to a National Provider Identifier checked against the NPPES registry. This keeps ordering limited to licensed professionals and gives each practice a single, traceable account rather than a shared login.

Setting up an account is a short intake step. Once verified, ordering, documentation requests, and lot-level records are handled through that account.

Cold-chain logistics into the Mountain West

Shipments to Utah move through the same cold-chain process used nationwide: cryopreserved products are held at -80 C, packed on dry ice in validated containers, and shipped overnight. We recommend practices confirm freezer capacity and a staffed receiving window before the first shipment arrives.

• Cryopreserved formats are stored at -80 C prior to shipment
• Orders ship overnight on dry ice in validated shipping containers
• Each lot carries a unique identifier for tracking at the patient record level

Confirming regulatory standing before you order

Whether a specific intended use of a Wharton's jelly or exosome product fits within a practice's existing scope of practice and regulatory framework is a determination for the practice and its own counsel, not something Precision Biologics advises on. We recommend confirming standing with the Utah medical board and legal counsel as part of any vendor qualification process.

For practices that want to talk through documentation in more detail, we offer physician-level calls focused on the paperwork itself, such as how to read a certificate of analysis or lot release record, not clinical guidance.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.